This study reveals that two sorafenib analogues, SC-1 and SC-43, that do not inhibit raf-1 kinase activity, show better anti-cancer effects in human breast cancer cells than sorafenib and that this improved efficacy is mediated by SHP-1-dependent p-STAT3 inhibition. This evidence concerns the gene NR0B2 and breast carcinoma.